search
Back to results

PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women

Primary Purpose

HIV/AIDS

Status
Completed
Phase
Not Applicable
Locations
Kenya
Study Type
Interventional
Intervention
PrEP My Way
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV/AIDS focused on measuring prevention

Eligibility Criteria

16 Years - 24 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Young woman (age 16-24 years); we will enroll emancipated minors (e.g., those who have not yet attained the age of legal competency as defined by state law, but who are entitled to treatment as if they had by virtue of assuming adult responsibilities, such as self-support, marriage, or procreation) per Kenyan national guidelines [39]) or 16-17 year-olds with parental consent
  • Reported sexual activity within the past 3 months
  • Interest in taking PrEP (actual PrEP uptake is not a requirement for Aim 1)
  • Residence in the Kisumu region
  • Phone ownership
  • Ability to understand KiSwahili, DhoLuo, and/or English

Exclusion Criteria:

  • Inability to provide informed consent (e.g., intoxication, mental disability)

Sites / Locations

  • Kenya Medical Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

PrEP My Way intervention

Control

Arm Description

PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.

These participants will continue to receive PrEP at the clinic.

Outcomes

Primary Outcome Measures

PrEP Adherence
PrEP adherence as measured by tenofovir-diphosphate (TFV-DP) in dried blood spot (DBS) testing

Secondary Outcome Measures

Self-reported PrEP adherence
PrEP adherence as measured by questionnaires
PrEP persistence
PrEP adherence as measured by pharmacy pick up over the six months
Rates of STI testing
Rates of pregnancy test and contraception pick up
Cost estimate
The study team will conduct a micro-costing analysis to assess the cost of the intervention in a standard clinic setting from the payer perspective. Cost will be presented as US dollars per intervention and sub-divided into amounts for capital goods, personnel, supplies, overhead, and training.

Full Information

First Posted
May 12, 2020
Last Updated
December 9, 2022
Sponsor
Massachusetts General Hospital
Collaborators
Kenya Medical Research Institute, Emory University
search

1. Study Identification

Unique Protocol Identification Number
NCT04408729
Brief Title
PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women
Official Title
"PrEP My Way": A Novel PrEP Delivery System to Meet the Needs of Young African Women
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
August 10, 2020 (Actual)
Primary Completion Date
October 26, 2022 (Actual)
Study Completion Date
October 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Kenya Medical Research Institute, Emory University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators will first develop, tailor, and refine PrEP My Way for use with young women in Kisumu, Kenya (Aim 1). The design firm will use a client-centered, iterative approach, involving up to 15 individual interviews and two focus group discussions (with up to 5 women each) to optimally design the PrEP My Way kit (with instructional materials) and peer delivery system (including communication and kit delivery plans). The investigators will then test the intervention for feasibility, acceptability, and preliminary impact on PrEP adherence and program retention (Aim 2). The study team will randomize 100 Kenyan women to PrEP My Way versus standard of care (i.e., clinic-based delivery of PrEP and sexual health services) and follow them for 6 months. Feasibility will be assessed by receipt of the kit at 1, 3, and 6 months and ability to use its components per protocol. Acceptability will be determined through a mixed-methods interview at 6 months. Preliminary impact will be evaluated by dried blood spot tenofovir levels (adherence) and kit use/clinic attendance at 6 months (retention) as primary outcomes. Mediators and moderators of PrEP use (e.g., empowerment and mental health) will be explored through questionnaires at baseline and 6 months.
Detailed Description
Develop PrEP My Way. Using a client-centered approach, the study team will iteratively conduct individual interviews and focus group discussions with up to 25 Kenyan women (age 16-24) to optimally design PrEP My Way (the kit with instructional materials) and peer delivery system (including phone communication and kit delivery plans). Assess PrEP My Way for feasibility, acceptability, and preliminary impact on PrEP adherence and program retention. The investigators will randomize 100 Kenyan women (age 16-24) to PrEP My Way versus standard of care (i.e., clinic-based delivery of PrEP and sexual health services) and follow them for 6 months. Feasibility will be assessed by receipt of the kit at 1, 3, and 6 months and ability to use its components per protocol. Acceptability will be determined through a mixed-methods interview. Preliminary impact will be evaluated by dried blood spot tenofovir levels (adherence) and kit use/clinic attendance at 6 months (retention). Potential influencing and mediating socio-behavioral factors will be explored with questionnaires at 0 and 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS
Keywords
prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PrEP My Way intervention
Arm Type
Experimental
Arm Description
PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
Arm Title
Control
Arm Type
No Intervention
Arm Description
These participants will continue to receive PrEP at the clinic.
Intervention Type
Other
Intervention Name(s)
PrEP My Way
Intervention Description
Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests). This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP.
Primary Outcome Measure Information:
Title
PrEP Adherence
Description
PrEP adherence as measured by tenofovir-diphosphate (TFV-DP) in dried blood spot (DBS) testing
Time Frame
Six months
Secondary Outcome Measure Information:
Title
Self-reported PrEP adherence
Description
PrEP adherence as measured by questionnaires
Time Frame
Months 1, 3, 6 (intervention arm), Month 6 (control arm)
Title
PrEP persistence
Description
PrEP adherence as measured by pharmacy pick up over the six months
Time Frame
Over the six month period
Title
Rates of STI testing
Time Frame
Months 1, 3, and 6
Title
Rates of pregnancy test and contraception pick up
Time Frame
Months 1, 3, and 6
Title
Cost estimate
Description
The study team will conduct a micro-costing analysis to assess the cost of the intervention in a standard clinic setting from the payer perspective. Cost will be presented as US dollars per intervention and sub-divided into amounts for capital goods, personnel, supplies, overhead, and training.
Time Frame
Six months
Other Pre-specified Outcome Measures:
Title
Feasibility of intervention use
Description
The PrEP My Way intervention will be considered feasible if >70% (35/50) participants 1) receive a kit at Months 1, 3, and 6; and 2) achieve a readable HIV test, usable vaginal swab, and self-injection of medroxyprogesterone, if desired, per protocol at >66% (2/3) of visits.
Time Frame
Six months
Title
Acceptability of intervention
Description
The PrEP My Way intervention will be considered acceptable if >70% (35/50) participants rate 70% (7/10) items on the Systems Usability Scale as "very good" or higher.
Time Frame
Six months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Young woman (age 16-24 years); we will enroll emancipated minors (e.g., those who have not yet attained the age of legal competency as defined by state law, but who are entitled to treatment as if they had by virtue of assuming adult responsibilities, such as self-support, marriage, or procreation) per Kenyan national guidelines [39]) or 16-17 year-olds with parental consent Reported sexual activity within the past 3 months Interest in taking PrEP (actual PrEP uptake is not a requirement for Aim 1) Residence in the Kisumu region Phone ownership Ability to understand KiSwahili, DhoLuo, and/or English Exclusion Criteria: Inability to provide informed consent (e.g., intoxication, mental disability)
Facility Information:
Facility Name
Kenya Medical Research Institute
City
Kisumu
Country
Kenya

12. IPD Sharing Statement

Learn more about this trial

PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women

We'll reach out to this number within 24 hrs